Tip: Try author name, DOI (10.xxxx/…), or keywords.

ISSN (Online): 1694-4674
Annals of Medicine and Medical Sciences
Submit Manuscript
  1. Home
  2. Volume 04 (2025), Version 10
  3. A Study of Association of Interleukin-6 and D-Dimer Levels with Outcom…
Original Article Open Access

A Study of Association of Interleukin-6 and D-Dimer Levels with Outcome in Patients of COVID-19

,,,,,,
Annals of Medicine and Medical SciencesVolume 04 (2025), Version 10 August 23, 2025pp. 954 - 960
718 247
Download PDF
Abstract

Introduction: Coronavirus disease 2019 (COVID-19) was declared as a pandemic by the World Health Organization (WHO) in March 20201. COVID-19 severity is linked to cytokine storm driven by IL-6 and elevated D-dimer levels, both indicating inflammation and thrombosis. This study aimed to find the association of level of IL-6 and D- Dimer with clinical outcome in COVID 19 patients. Materials and Methods: This retrospective, cross-sectional single-centre study analyzed 484 adult COVID-19 patients admitted in a tertiary care centre over a period of one year. It assessed comorbidities, IL-6 and D-dimer levels, and their correlation with outcomes like ICU admission, oxygen need, and mortality. Data were analyzed using OpenEpi, MS Excel, and S.P.S.S. with descriptive stats, chi-square, and correlation tests. Results: Most common (41.5%) age group involved was 41-60 years with 72.31% males and 27.69% females. Diabetes (50.3%), and hypertension (25.9%), were the most common comorbidities observed. 24.79% had raised D- dimer level and 29.13% patients showed raised IL-6 level. Higher IL-6 (Chi- square =226.0, p < 0.000001) and D-Dimer (chi- square = 362.4, p < 0.00001) levels were strongly associated with COVID-19 mortality. Conclusion: Investigations like IL-6 & D Dimer can be useful to assess the prognosis.

References
  1. [1] M.Z T, Poh CM, Renia PA, MacAry PA. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363–74.
  2. [2] Wu YC, Chen CS, Chan YJ. "The outbreak of COVID-19: An overview". Journal of the Chinese Medical Association.2020;83 (3): 217–220.
  3. [3] Wang C, Horby PW, Hayden FG et al. "A novel coronavirus outbreak of global health concern". Lancet. 2020;395 (10223): 470–473.
  4. [4] Cohen J. "Wuhan seafood market may not be source of novel virus spreading globally". Science. January 2020.
  5. [5] "Novel Coronavirus – China". World Health Organization (WHO). 12 January 2020.
  6. [6] Kessler G. "Trump's false claim that the WHO said the coronavirus was 'not communicable'". The Washington Post. 17 April 2020.
  7. [7] "China delayed releasing coronavirus info, frustrating WHO". AP NEWS. 2020.
  8. [8] World Health Organization Coronavirus Disease (COVID-19) Situation Report– 169. Data as Received by WHO from National Authorities; 7 July, 2020.
  9. [9] Sawicki SG, Sawicki DL. Coronavirus transcription: A perspective. Curr Top Microbiol Imm 2005; 287:31-55.
  10. [10] Su S, Wong G, Shi W et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016; 24:490-502.
  11. [11] Bosch BJ, van der Zee R, de Haan CA et al. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. Journal. 2003;77:8801-8811. 88
  12. [12] Ou X, Liu Y, Lei X et al. Characterization of spike glycoprotein of SARSCoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Journal. 2020;11:1620.
  13. [13] Yoshikawa T, Hill T, Li K et al. Severe acute respiratory syndrome (SARS) coronavirus induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells. Journal. 2009;83:3039– 3048.
  14. [14] Qin C, Zhou L, Hu Z et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Journal. 2020.
  15. [15] Koutsogiannaki S, Shimaoka M, Yuki K. The use of volatile anesthetics as sedatives for acute respiratory distress syndrome. Journal. 2019; 6:27-38.
  16. [16] Fang M, Siciliano NA, Hersperger AR et al. Perforin-dependent CD4+ T-cell cytotoxicity contributes to control a murine poxvirus infection. Journal. 2012;109:9983–9988
  17. [17] Sluimer JC, Gasc JM, Hamming et al. Angiotensin-converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions. Journal. 2008; 215:273–279.
  18. [18] Pearce L, Davidson SM, Yellon DM. The cytokine storm of COVID-19: a spotlight on prevention and protection. Expert Opin Ther Targets. 2020;27:1-8.
  19. [19] Poudel A, Poudel Y, Adhikari A, Aryal BB, Dangol D, Bajracharya T, et al. Ddimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19.
  20. [20] De Souza R, Mhatre S, Qayyumi B, Chitkara G, Madke T, Joshi M, et al. Clinical course and outcome of patients with COVID-19 in Mumbai City: An observational study. BMJ Open. 2021;11(5)
  21. [21] Martinez-Urbistondo M, Mora-Vargas A, Expósito-Palomo E, Castejón R, Citores MJ, Rosado S, et al. Inflammatory-related clinical and metabolic outcomes in Covid-19 patients. Mediators Inflamm. 2020;2020
  22. [22] Talwar D, Kumar S, Acharya S, et al. Interleukin 6 and Its Correlation with COVID-19 in Terms of Outcomes in an Intensive Care Unit of a Rural Hospital: A Cross-sectional Study. Indian J Crit Care Med. 2022;26(1):39-42.
  23. [23] Soni M, Gopalakrishnan R, Vaishya R, Prabu P. D-dimer level is a useful predictor for mortality in patients with COVID-19: Analysis of 483 cases. Diabetes Metab Syndr. 2020;14(6):2245-2249.
  24. [24] Li P, Chen L, Liu Z et al. Clinical features and short-term outcomes of elderly patients with COVID-19. International Journal of Infectious Diseases. 2020; 97:245–250. 107.
  25. [25] Avila-Nava A, Cortes-Telles A, Torres-Erazo D, López-Romero S, Chim Aké R, Gutiérrez Solis AL. Serum IL-6: A potential biomarker of mortality among SARS-CoV-2 infected patients in Mexico. Cytokine. 2021 Jul;143:155543.
  26. [26] Jain SK, Dudani A, Jaiswal N, Deopujari K, Simmi Dube S. Assessment of Clinical Profile & Risk Factors Associated with Adverse Outcome in COVID-19 Patients at a Tertiary Care Hospital in Central India - A Retrospective Record Based Study. J Assoc Physicians India. 2021 Apr;69(4):27-31.
  27. [27] Yao Y, Cao J, Wang Q, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J Intensive Care. 2020;8:49. Published 2020 Jul 10.
  28. [28] de Souza R, Mhatre S, Qayyumi B, et al.. Clinical course and outcome of patients with COVID-19 in Mumbai City: an observational study. BMJ Open. 2021 May 6;11(5):e042943.
  29. [29] Guan WJ, Ni ZY, Hu Y. Clinical characteristics of corona virus disease2019 in China. N Engl J Med. 2020;382(18):1708–20.
  30. [30] El-Shabrawy M, Alsadik ME, El-Shafei M, Abdelmoaty AA, Alazzouni AS, Esawy MM, Shabana MA. Interleukin-6 and C-reactive protein/albumin ratio as predictors of COVID-19 severity and mortality. Egypt J Bronchol.2021;15(1):5.